Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
NCT04582864 · Washington University School of Medicine · PHASE2 · terminated · last registry update 2024-12-06 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor is no longer supporting the drug” | Open Targets' class: business administrative | Registry record, Washington University School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL3RA in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-30Also stopped (terminated): Gruppo Italiano Malattie EMatologiche dell'Adulto, tagraxofusp (NCT04342962)
- 2024-10-17Also stopped (terminated): Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-21Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-01Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp (NCT02113982)
- 2024-03-08Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Azacitidine + Tagraxofusp-erzs (NCT05720988)
- 2024-01-30Results posted on the registry: MacroGenics, Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off + Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (NCT02152956)
- 2024-01-30Also stopped (terminated): MacroGenics, Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off + Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (NCT02152956)
- 2023-12-11Results posted on the registry: Children's Oncology Group, Cytarabine + Flotetuzumab (NCT04158739)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision